---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-006754"
form_type: "8-K"
ticker: null
cik: "0001629205"
company_name: "Innovation1 Biotech Inc."
filed_at: "2023-09-08T23:59:59+00:00"
generated_at: "2026-06-10T22:12:05.387292+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Innovation1 Biotech closes $78,695 secured convertible note + warrant financing

## Summary
- Gross proceeds of $66,891 from $78,695 principal amount 8% secured convertible notes due Sept 30, 2024.
- Notes convertible at $0.08/share; 983,693 warrants issued with $0.08 exercise price.
- Transaction completed with two purchasers; securities unregistered under Rule 506(b).
- Notes include 4.99% beneficial ownership limitation and secured by company assets.

## SEC filing metadata
- accession: 0001477932-23-006754
- form_type: 8-K
- cik: 0001629205
- company_name: Innovation1 Biotech Inc.
- filed_at: 2023-09-08T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1629205/000147793223006754/0001477932-23-006754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1629205/000147793223006754/ivbt_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-006754
- JSON: https://secwatch.observer/filing/0001477932-23-006754.json
- Plain text: https://secwatch.observer/filing/0001477932-23-006754.txt

## Key facts
- Debt Financings
  Innovation1 Biotech Inc. incurred convertible notes of $78,695 with two lenders (the "Purchasers") at 8% per annum maturing September 30, 2024.
  - Instrument: convertible notes
  - Principal: $78,695
  - Counterparty: two lenders (the "Purchasers")
  - Rate: 8% per annum
  - Maturity: September 30, 2024
  - Event: incurrence
  source text: On September 1, 2023, Innovation1 Biotech Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with two lenders (the “Purchasers”), pursuant to which the Company issued and sold the Purchasers Original Issue Discount Secured Convertible Promissory Notes in the principal amount of $78,695 (collectively, the “Notes”) for gross proceeds of $66,891.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1629205/000147793223006754/0001477932-23-006754-index.htm
- Material Agreements
  Innovation1 Biotech Inc. entered into Securities Purchase Agreement with two lenders (the “Purchasers”) valued at principal amount of $78,695 (effective 2023-09-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: two lenders (the “Purchasers”)
  - Value: principal amount of $78,695
  - Effective: 2023-09-01
  source text: On September 1, 2023, Innovation1 Biotech Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with two lenders (the “Purchasers”), pursuant to which the Company issued and sold the Purchasers Original Issue Discount Secured Convertible Promissory Notes in the principal amount of $78,695 (collectively, the “Notes”) for gross proceeds of $66,891.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1629205/000147793223006754/0001477932-23-006754-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.